$NBIO SAN DIEGO, CA / ACCESSWIRE / March 24, 2021
Post# of 18240
Screening to enroll patients in the trial is already underway. Those interested may review trial requirements here: https://www.clinicaltrials.gov/ct2/results?te...mp;phase=0
PTB is a natural human antibody that works by binding to Cell surface Vimentin (sometimes referred to as ectodomain vimentin, or EDV), a protein expressed on the surface of epithelial cancers. The PTB antibody is used as a targeted immunotherapy, which unlike chemotherapy, targets only the cancer cells without damaging healthy cells.